Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses.
CHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
ASCO26: In vivo oncology approaches continue to show promise
Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
Akeso, Summit drug extends survival in closely watched lung cancer trial
How HER2 biology is shaping next-generation cancer treatment
For pancreatic cancer patients, an exciting drug can feel out of reach
Trial offers fresh hope for patients resistant to standard cancer treatments - World News
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1…
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Editor's Note: The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three…
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
